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Summary The anti-tumour antibody-dependent cell-mediated cytotoxicity (ADCC) capacity of the conven-
tional antibody ml7-IA was compared with its chimerised analogue c17-lA and a newer chimeric antibody.
cSF25. specific for colonic adenocarcinoma. The results (AUC units±s.e.m.. control versus cancer) show that
mononuclear cells from patients with adenocarcinoma mediate ADCC as efficiently as those from controls for
m17-lA (143 ± 14 vs 153 ± 14). c17-1A (174 16 vs 189 ± 14) cSF25 (215 ± 18 vs 237 ± 13) and effectors and
targets alone (57 ± 9 vs 51 ± 8). Both chimeric antibodies mediated ADCC more effectively than ml7-lA with
cSF25 consistently producing the highest lysis. Furthermore, more efficient ADCC was found to correspond
with monocyte activation examined flow cytometrically. The results (mean channel fluorescence) show that
HLA-DR expression is increased with c17-lA (1436 + 200) and cSF25 (2252 ± 298) above that observed when
effectors and targets were incubated alone (1157 ± 168) or with m17-IA (1286 + 170). Similarly. interleukin 2
receptor (IL-2R) expression (percentage of positive cells) was augmented in the presence of m17-lA (15 3).
c17-lA (14 ± 3) and cSF25 (25 ± 3) when compared with no antibody (9 ± 2). We discuss the possibility that
the superior ADCC activity of chimeric antibodies, especially cSF25. may be due to increased monocyte
activation.
The administration of murine monoclonal antibodies (MAbs)
in humans for diagnostic and therapeutic purposes has been
limited by their short circulating half-life and immuno-
genicity. Murine MAbs have circulating half-lives of 15-30 h
in humans (Pimm et al.. 1985; Khazaeli et al., 1988) and thus
may require frequent. repeated administration (Khazaeli et
al., 1988). In addition. the majority of patients develop an
immune response to this foreign protein that is manifested by
the appearance of circulating human anti-mouse antibodies
(HAMAs) 10-30 days following exposure (Sears et al.,
1982). This HAMA response has been reported to alter
pharmacokinetics and prevent circulating of the murine anti-
body and may lead to allergic reactions (Pimm et al., 1985;
Khazaeli et al., 1988).
In an attempt to overcome these problems, chimeric anti-
bodies have been produced. These are genetic constructs
having the variable region of mouse MAbs and the constant
regions of human immunoglobulins (Morrison et al., 1984).
Chimeric antibodies have similar binding affinity (Sun et al.,
1987; Buschbaum et al.. 1990) to their murine counterparts
as well as a similar (Liu et al., 1987a; Shaw et al., 1987, 1988)
or supenor (Liu et al., 1987b; Nishimura et al., 1987; Mas-
succi et al.. 1988) ability to mediate cell-mediated cytotox-
icity. These molecules have been shown to have improved
biological activity and longer circulating half-lives and most
appear to have reduced immunogenicity in humans (LoBug-
lio et al., 1989).
Monoclonal antibodies directed against tumour-associated
antigens may bring about tumour lysis by antibody-depen-
dent cell-mediated cytotoxicity (Herlyn et al., 1979).
Although most MAbs used as anti-cancer agents are tumour
selective, they are not tumour specific and may bind to
non-malignant tissue, reducing their therapeutic efficacy and
potentially increasing cytotoxicity. We therefore examined a
recently developed chimeric antibody, cSF25, which appears
to be more specific for colorectal cancer, for its ability to
mediate ADCC (Takahashi et al., 1988, 1989). We compared
it with the anti-colorectal cancer antibodies, murine 17-lA
(ml7-lA) and chimeric 17-lA (c17-4A), which are known to
bind to normal colonic mucosa as well as to gastrointestinal
adenocarcinomas (Gottlinger et al., 1986; Sun et al., 1987).
In addition, since monocytes are thought to be important
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mediators of ADCC (Herlyn & Cowprowski. 1982; McCarley
et al.. 1983; Steplewki et al., 1983. 1986; Adams et al.. 1984:
Johnson et al.. 1986; Ortaldo et al., 1987; Hellstrom et al..
1988; Massucci et al.. 1988), we examined monocyte activa-
tion markers in the presence of each of the three antibodies.
Materias and nethods
Patients and controls
In the first part of the study, peripheral blood mononuclear
cells (PBMCs) were isolated from 29 patients with adenocar-
cinoma and 22 control subjects (Table I). These PBMCs were
used in an ADCC assay using each of the three antibodies
m17-4A, c17-lA and cSF25. In the cancer group, the patients
had primary tumours or recurrent disease. Twenty-six
patients had advanced disease as determined by the presence
of lymph node involvement or distant metastases. The con-
trol subjects were age- and sex-matched patients with benign
conditions. Both patient groups were preoperative with no
evidence of sepsis and none was receiving any form of
immunosuppressive medication at the time of study. In the
second part of the study, 19 patients were studied for mono-
cyte HLA-DR expression and 11 for monocyte IL-2 receptor
expression. These patients all had adenocarcinoma and were
a subset of the group already described.
Antibodies
Three antibodies to tumour antigens were used, murine 17-
IA, chimeric 17-lA and chimeric cSF25, which are IgG2a,
IgGI and IgGI antibodies respectively. All bind to surface
antigens expressed on colorectal adenocarcinoma (Gottlinger
et al., 1986; Sun et al., 1987; Takahashi et al., 1988, 1989).
Irrelevant antibodies of identified isotype were also tested as
non-specific controls. For the chimeric antibodies, the control
used was a chimerised IgGI antibody, 7E3, which binds to
the platelet membrane glycoprotein Ilb/IlIa. RDlIDIO, an
IgG2a murine antibody that reacts with cardiac myosin, was
used as a murine control. All antibodies were kindly pro-
vided by Centocor (Malvern, PA, USA).
Target cell cultures
The colorectal cancer cell lines, LS180 and SW 1116, were a
gift from Centocor. Colo320 was obtained from the Euro-
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Table I Patient demographics for the two study groups
Cancer Controls
n 29 22
M:F 15:14 8:14
Age 68 68
Range (43-84) Range (49-87)
Colorectal 13
Gastnrc 9
Breast 3
Pancreas I
Ovars
Loss of body weight 3 0
>100
Serum albumin <35 gdl-' 0 0
pean Tissue Culture Collection (Porton Down. Salisbury.
UK). Cultures were maintained in 75 cmr' tissue culture flasks
(Sterilin Laboratories, Feltham, UK) using RPMI medium
1640 (ICN Flow Laboratories, Irvine, UK) supplemented
with 10% heat-inactivated fetal calf serum (FCS) (Techgen
International, France), 100 IU ml-' penicillin and 100 mg
ml-' streptomycin at 37°C in a humidified atmosphere con-
taining 5% carbon dioxide. After 3-4 days when the cells
had grown to confluence. they were harvested by 10 min
incubation with 10% trypsin (ICN Flow Laboratories,
Irvine, UK) and resuspension in RPMI-1640 with 10% FCS.
All cultures were tested to be free of myocoplasma.
Purification ofeffector cells
Peripheral blood was drawn into heparinised tubes. Peri-
pheral blood mononuclear cells were isolated by Ficoll-
Hypaque density centrifugation and isolation of the interface.
After three washes in phosphate-buffered saline (PBS, ICN
Flow Laboratories), the cells were resuspended in RPMI-
1640 supplemented with 10% FCS.
ADCC assa}
The ADCC capacity of peripheral blood mononuclear cells
from different donors was studied using an 18 h chromium-
51 release assay. Approximately 5 x 106 LS180 target cells
were labelled with 150 jiCi of ['Cr]sodium chromate (Radio-
chemical Centre, Amersham, UK) in 500 gl of PBS for 1 h at
37°C. After three washes they were resuspended in culture
medium at a concentration of 2 x 10 cells ml-'. Approx-
imately I04 cells in 50 lal of medium were placed in each well
of a 96-well plate (Nunc Intermed, Denmark) and 50;1l of
effector cells was added to give effector to target cell ratios of
100, 50, 25 and 12.5. A 10IlI volume of antibody was added
to give a final concentration of 10.4f.g I-i. All samples were
run in triplicate. Effector cells and target cells without
antibody were used as negative controls. Both effector cells
and targets had >95% viability as assessed by trypan blue
exclusion. The plates were incubated for 18 h at 37°C in a
humidified atmosphere containing 5% carbon dioxide, and at
the end of this period the plates were centrifuged to pellet the
cells.
Aliquots of 70 glI of supernatant were aspirated and
counted in a gamma counter. The spontaneous release was
measured from wells to which culture medium alone was
added, and the maximum release was measured on wells to
which 5% Triton X had been added. The percentage specific
lysis was calculated according to the formula
Lysis (%) release in sample - spontaneous release x 100
maximum release - spontaneous release
Cytotoxicity date were analysed by measuring the area
under the curve (AUC) of four effector-target ratio points
(Dye et al.. 1991). The results are therefore expressed as
AUC units ± standard error of the mean.
All three anti-colorectal antibodies and non-specific control
antibodies were tested in parallel within the same experiment
using lymphocytes from either cancer patients or healthy
subjects. The experiment was repeated on two further colo-
rectal cell lines, SWI116 and Colo320, to ensure that any
result observed with LS180 was not cell line specific. For
these experiments. PBMCs from control subjects were used.
There were two groups of nine healthy volunteers who had
not been studied previously.
Preparation ofcellsforflow cvtometrv
An ADCC assay was performed as described above but using
non-radiolabelled LS180 target cells. At the end of the 18 h
incubation, the cells were pelleted, the supernatant aspirated
and the remaining target cells were resuspended in PBS. A
100jil aliquot of this cell suspension was then added to 10 pl
aliquots of FITC-conjugated anti-Leu M3 to identify the
monocyte population. The suspension was then incubated for
30 min with either phycoerythrin-stained anti-interleukin 2
receptor or anti-HLA DR (human leucocyte antigen) recep-
tor monoclonal antibodies (Becton Dickinson, Cowley,
Oxford. UK) as markers of monocyte activation. These pro-
cedures were carried out in lipopolysaccharide (LPS)-free
polypropylene plastics at 4'C in the dark. The samples were
then washed twice in modified Dulbecco's PBS without cal-
cium or magnesium but with added EDTA. bovine serum
albumin (BSA) and sodium azide (Sigma. Dorset, UK). Sam-
ples were then run through a FACScan flow cytometer utilis-
ing Consort acquisition software and Lysis analysis software
(Becton Dickinson).
Measurement of monocyte HLA-DR expression was car-
ried out as follows. The monocyte population was gated on
by virtue of its light-scattering properties and the FITC-
labelled Leu-M3-positive cells identified. This gate was then
plotted as a frequency histogram of red fluorescence to
measure HLA-DR expression. The results are expressed as
an arithmetic mean fluorescence, a measure of the level of
monocyte HLA-DR expression (>97% of the monocyte gate
was positive for HLA-DR). For IL-2 receptor expression,
again Leu-M3-positive cells were identified and a frequency
histogram of red fluorescence plotted, but this time results
are expressed as a percentage of positive cells (approximately
10% of the monocyte gate was positive for the IL-2 recep-
tor).
Statistical anals sis
Significance within each patient group was determined using
Student's paired t-test and by Student's unpaired t-test
between groups. A probability of less than 5% (P<0.05)
was considered significant.
Results
Comparison ofADCC capacity between patient groups
There was no significant difference between effector cells
from patients with adenocarcinoma and from controls in
their ability to mediate ADCC. Mean AUC values ± s.e.m
were similar for the adenocarcinoma group (51 ± 8) and the
control group (57 ± 9) when no antibody was used in the
assay. As expected, all three antibodies mediated significantly
greater target cell lysis than effector cells alone, but there was
no significant difference between the cancer and control
patients. For cancer patients versus controls, the AUC values
were 153 ± 14 vs 143 + 14 for m17-lA. 189 + 14 vs 174 + 16
for c17-1A and 237 ± 13 vs 215 ± 19 for cSF25.
The patients' age, haemoglobin concentration, white cell
count, plasma bilirubin, protein or albumin concentration
did not correlate with tumour lysis by effector cells alone, or
with any of the three antibodies as determined by regression
analysis. Furthermore, ADCC capacity was not significantly
influenced by the type of malignancy or clinical stage (Table
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Table 11 AUC values±s.e.m. for ADCC mediated by PBLs from
cancer patients with each antibody
No antibody ml7-lA ci7-lA cSF25
Colorectal 49± 11
(n= 13)
Oesophagogastnrc 61 ± 18
(n = 9)
Breast 70±40
(n = 3)
Pancreatic ovanran 29±9
(n = 4)
Localised disease 82 ±98
(n = 3)
Advanced disease 47 ± 8
(n = 26)
Weight loss 16±2
>1000 (n =3)
Weight loss 55±8
<lO01o (n=26)
148±21 170± 19 217± 14
172±34 220±33 258±27
194±112 252± 145 311± 179*
143± 17 166±37 231 ±51
104±33 138±33 229±82
158± 14 194± 14 238± 13
85±29 151 ±32 218±21
160± 14 192± 15 239± 14
AUCvalues±s.e.m. forADCmediated by PBLsfromcancerpatients
with each antibody. AUC values are given according to type of
malignancy, presence of advanced disease and nutritional status as
denoted by degree ofweight loss. These differences were not significant
except *P = 0.01 when comparing ADCC mediated by cSF25 using
PBLs from patients with breast cancer with those from patients with
colorectal cancer.
Comparison ofADCC capacityfor each antibod-
We found a consistent and significant pattern with the anti-
bodies in their ability to mediate ADCC (Figures 1 and 2). In
patients with adenocarcinoma, when compared with effector
cells alone, ml7-lA. cI7-IA and cSF25 produced significant-
ly better tumour lysis. c17-IA was superior to ml7-lA and
cSF25 was significantly better than either ml7-la or c17-IA
(Figure 1). Similarly, in the control group, the pattern was
the same (Figure 2). The AUC units approximated to levels
of cytotoxicity of roughly <10% for effectors only. 20-30%
for m17-iA, 30-40% for c17-4A and 50-60% for cSF25.
The non-specific control antibodies did not produce an
increase in tumour lysis above that seen in the absence of
antibody (Figure 3). The murine irrelevant antibody,
RI 1DI0. produced approximately the same level of killing as
that seen with effector cells alone. Surprisingly, the chimeric
antibody c7E3 produced less killing than effector cells alone.
We have not investigated this further, but since this antibody
binds to platelet membranes the reduced cell lysis may pos-
sibly be due to platelet aggregation producing steric hind-
rance of the ADCC reaction.
Comparison ofADCC capacity between cell lines
Small patient groups (n = 9) were used to test the ADCC
assay in two additional colorectal cell lines, SW I I 6 and
Colo321, and in each case the pattern of antibody-mediated
lysis was the same as that observed with LS180 in the larger
patient groups. Using Colo320 (Figure 4), tumour cell lysis
was significantly greater with cSF25 (339 ± 12), cl7-IA
(174 ± 28) and m17-lA (147 ± 29) than when effector cells
alone (70 ±16) were used. Similarly, with SWiI16 (Figure
5). cSF25 (296 ± 18), c17-iA (257 ± 24) and mi7-iA (196 +
16) produced significantly more tumour lysis than in the
absence of antibody (65 ± 13).
Monocvte activation markers
Monocyte HLA-DR and IL-2 receptor expression were both
significantly increased above baseline by 18 h incubation
without the presence of either target cells or antibody. The
results are expressed as mean values of mean channel fluo-
rescence (MCF) for HLA-DR, with the mean MCF being
148 ± 70 for effector cells alone before incubation, increasing
to 1.157 ± 168 after 18 h incubation. The percentage of cells
expressing the IL-2 receptor increased from 1.43 ± 0.55 to
8.93 ± 2.44 after 18 h incubation without either target cells or
antibody. The mature antibody ml7-lA did not significantly
augment levels of monocyte HLA-DR (1.287 ± 171) expres-
sion in comparison with that produced when monocytes
alone were incubated with tumour cells (1.157 ± 168). but the
300 r
*4:
200-
100-
No antibody m17-lA c17-lA cSF25
Figure 1 AUC units for ADCC mediated by m17-1A. c 17-1A
and cSF25 compared with lysis mediated by effector cells alone
against the cell line LS180. Results show mean values ± s.e.m. for
ADCC assays performed with lymphocytes from 29 cancer
patients. *Increase above no antibody (P<0.0001). tincrease
above m17-1A (P=0.001). +increase above m17-lA and c17-lA
(P<0.0001).
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Figre 2 AUC units for ADCC mediated by m17-1A. cl7-1A
and cSF25 compared with lysis mediated by effector cells alone
against the cell line LS180. Results show mean values ± s.e.m. for
22 control patients. *Increase above no antibody (P<0.0001).
tincrease above ml7-lA (P = 0.008). increase above m17-lA
(P<0.0001) and c17-lA (P<0.0001).
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Figue 3 This graph demonstrates ADCC mediated by the
irrelevant antibodies. RIIDI0 and c7E3 against the three cell lines
LS180 ([=O) SW 116 ( ) and Colo320 (_) expressed as
mean AUC values ± s.e.m.
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Figur 4 AUC units for AD-CC mediated by m17-1A. cl7-1A
and cSF25 compared with lysis mediated by effector cells alone
against the cell line Colo320. Results show mean value±s.e.m.
for nine control subjects. *Increase above no antibody (P<0.05).
tincrease above m17-1A and c17-lA (P<0.001).
Fiue 6 HLA-DR expression on monocytes from 19 subjects
after incubation with target cells alone or after ADCC assay with
m17-4A. c17-lA or cSF25. Results are expressed as mean values
for mean channel fluorescences±s.e.m. *P<0.0001 vs no
antibody, tP<0.001 vs m17-4A, P<0.002 vs c17-4A and m17-
IA.
c17-1A cSF25
Figure 5 AUC units for ADCC mediated by ml7-lA. c17-lA
and cSF25 against the cell line SWI 116. Results show mean
value ± se.m. for nine control subjects. *Increase above no
antibody (P<0.0001). tincrease above ml7-lA (P<0.0001).
+Increase above m17-la and c17-JA (P<0.002).
presence of either c17-lA (1,437 ± 200) or cSF25 (2,252
299) antibodies dunrng the 18 h incubation period produced a
significant increase above this value. Furthermore, cSF25
(2,252 ± 299) produced a level of HLA-DR expression that
was significantly greater than either 17-lA antibody (Figure
6).
Monocyte IL-2 receptor expression was significantly in-
creased in the presence of each of the three antibodies
(Figure 7). When compared with no antibody (8.93 ± 2.44),
ml7-lA (15.32±2.94), c17-lA (14.30±2.76) and cSF25
(25.56 ± 3.15) produced increased expression. In addition, the
presence of cSF25 during the incubation period induced
significantly greater IL-2 receptor expression than either ml7-
IA or c17-lA.
Discus
Monoclonal antibodies are thought to bring about tumour
cell destruction via antibody-dependent cell-mediated cyto-
toxicity (Herlyn et al., 1979). By this mechanism, effector
cells expressing receptors for the Fc portion of IgG
specifically bind to antibody attached to target cells and
mediate lysis (Steplewski et al., 1983, 1988; Lubeck et al.,
1985; Graziano & Fonger, 1987). In order for a monoclonal
antibody to bring about ADCC, it must recognise an epitope
on the tumour cell surface and ideally, for therapeutic and
diagnostic purposes, this antigen should be tumour specific.
The chimeric antibody used in this study. cSF25, was pro-
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Figue 7 IL-2 receptor expression on monocytes from 14 subjects
after incubation with target cells alone of after ADCC assay with
m17-lA. c17-lA or cSF25. Results are expressed as mean values of
percentage positive cells ± s.e.m. P<0.009 vs no antibody,
tP=0.001 vs m17-4A, P<0.0001 vs c17-4A.
duced against a hepatoma cell line, FOCUS, and binds to a
125,000 kDa cell-surface antigen. It has been found to react
strongly with all colorectal cancer cell lines tested and human
colonic adenocarcinomas obtained at surgery and, most
importantly, not to normal tissues, as shown by immuno-
peroxidase staining and direct binding to membrane prepara-
tions (Takahashi et al., 1988). In contrast, the 17-lA antigen
is known to be expressed on both normal colonic mucosa as
well as on adenocarcinomas of gastrointestinal orgin (Got-
linger et al., 1986; Sun et al., 1987).
We examined tumour lysis in vitro by comparing the ability
of this new antibody, cSF25, to mediate ADCC with the
ability of conventional 17-lA antibodies using PBMCs
derived from patients with mainly colorectal cancer. The
results shown that the chimeric antibodies, c17-lA and
cSF254, were both more effective in mediating tumour cell
lysis than the murine antibody, m17-lA. This superior anti-
tumour effect of chimeric 17-lA compared with ml7-lA has
previously been demonstrated (Massucci et al., 1988). How-
ever, cSF25 proved itself to be consistently and significantly
better than either chimeric 17-lA or its murine counterpart.
This effect was antigen specific since the two isotype control
antibodies produced no killing above that seen with effector
cells alone. In addition, the amount of killing relative to each
antibody showed the same pattern with two additional colo-
rectal cancer target cell lines. This eliminated a cell line-
specific effect and suggested that our results were not related
to a variation in antigen density on the cell surface. In
addition, none of the antibodies tested had a tumour lytic
CD
a-)
._
100
300 -
*l
-l
C 200 C-
Z)m
TI-
lvo -
No antibody m17-1A
us . U
. . . . . . . .
ul
I I _u I I L n(
X a a
T T
ILcSF25. MONOCYTES AND ADCC 757
effect when incubated with tumour cells alone. eliminating a
direct toxic effect.
Previous reports have suggested that ADCC capacity may
be either reduced (Stratton et al.. 1977; McCredie. 1979) or
increased (Hersh et al.. 1982) in patients with malignancy.
This has important implications clinically since, to date.
monoclonal antibodies have mainly been used to treat
patients with metastatic disease. It has been suggested that.
since these patients have advanced malignancy, they may be
immunosuppressed and hence less able to mediate ADCC
than their healthy counterparts. In an attempt to address this
point, we have shown that PBMCs from patients with adeno-
carcincoma were able to mediate ADCC as well as those
from healthy controls. We found no difference in ADCC
capacity between the different types of malignancy studied.
however the numbers of patients in the breast, pancreatic
and ovarian cancer groups were small. This was also a
problem when relating ADCC capacity to clinical stage, since
only three of the 29 patients with malignancy had local
disease. This, however. does suggest that patients with
advanced malignancy can produce normal levels of ADCC.
at least with ml7-lA, c17-lA and cSF25.
Of the effector cells known to mediate anti-tumour ADCC.
monocytes have been shown to constitute an important
population. In nude mice. silica treatment, which primarily
inactivates macrophages, abolished the tumoricidal effect of
monoclonal antibody (Adams et al., 1984). In addition, after
treatment with monoclonal antibody, tumours grown in nude
mice contained an increased number of macrophages which
were able to mediate ADCC (McCarley et al.. 1983). More
importantly, human monocytes have been shown to mediate
anti-tumour ADCC (Johnson et al.. 1986; Hellstrom et al..
1988). We therefore studied the monocyte component of the
PBMC population by measuring expression of activation
markers during the ADCC assay.
The results demonstrate an increased expression of both
HLA-DR and IL-2R, confirming significant monocyte activa-
tion in the presence of each of the three anti-colorectal
monoclonal antibodies. This was especially apparent with the
two chimeric antibodies, cl7-lA and cSF25. cSF25 signifi-
cantly increased expression of both HLA-DR and IL-2R
above either ml7-lA or c17-lA. and it is tempting to suggest
that the ability of cSF25 to mediate high levels of ADCC
may be due to this superior ability to activate monocytes.
This activation may be either direct or via cytokines pro-
duced by other cells within the PBMC population. These
monocytes may then in turn produce tumour lysis via cyto-
kine-mediated cellular cytotoxicity or by a direct mechanism.
Studies are in progress to determine the role of the mono-
cyte-derived cytokines, tumour necrosis factor alpha and
interferon gamma in the ADCC assay in an attempt to
clarify this point.
Although we have specifically examined activation markers
present on monocytes, the effector cell population studied
was not a pure monocyte preparation. There may therefore
be an additional antibody effect on other cell populations
which has not been elucidated here. A mixed population of
effector cells is more analogous to the in vivo state, but our
conclusions must be limited until we repeat this study utilis-
ing a pure monocyte preparation.
Chimeric monoclonal antibodies were engineered in the
hope that they would reduce HAMA production and allergic
reactions. We have demonstrated that in vitro the anti-
colorectal chimeric antibodies tested are more efficient at
mediating antibody-dependent tumour lysis than their murine
counterparts, which supports their use as a therapeutic
option. Furthermore. this occurs as effectively with effector
cells derived from patients with malignancy as with those
from their normal healthy counterparts. suggesting that this
effect will remain in patients with malignancy. In addition.
we have shown that cSF25 has superior tumour lytic ability
than the other antibodies tested. Since this antibody has been
demonstrated to be a more specific antibody for colorectal
cancer, it may be a promising therapeutic agent since the lack
of target specificity of many monoclonal antibodies is
thought to be partly responsible for their disappointing
therapeutic effect in vivo. Finally, the data also suggest that
efficiency ofADLCC is reflected by increased monocyte activa-
tion. and this may provide a possible target for in vivo
augmentation of ADCC. However, whether this monocyte
activation is important in mediating tumour cell lysis is a
focus of further investigation.
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